Healthcare >> CEO Interviews >> October 26, 2004
ROBERT J. DELUCCIA joined the Board of MacroChem Corporation in 2000 and
accepted the position of President and Chief Executive Officer and Vice
Chairman of the Board in June 2003. He has over 30 years' industry
experience with both large International pharmaceutical companies and
publicly held biopharmaceutical companies. Mr. DeLuccia is the former
President and Chief Executive Officer of Immunomedics, Inc., a NASDAQ
biopharmaceutical company focused on the development and
commercialization of antibody diagnostic imaging and therapeutic
products for cancer and infectious diseases. Prior to Immunomedics, he
was President of Sterling Winthrop Pharmaceuticals, the US subsidiary of
Sanofi (now Sanofi-Sythelabo). Mr. DeLuccia began his career as a
pharmaceutical sales representative for Pfizer and progressed to Vice
President, Marketing and Sales Operations for Pfizer's Roerig Division.
He is also a member of the Board of Directors of IBEX Technologies, a
publicly traded (TSX) biopharmaceutical company specializing in the
development of biological markers for diagnosis, monitoring and
treatment of arthritis and cancer. Profile
technology and business focus?
Mr. DeLuccia: I think we can best describe the company by saying that we
are a clinical
